Quadrature Capital
BCYC icon

Quadrature Capital’s Bicycle Therapeutics BCYC Stock Holding History

Quadrature Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Buy
+104,092
New +$477K ﹤0.01% 1056
2026
Q1 		– Sell
-46,728
Closed -$331K – 1386
2025
Q4 		$331K Buy
46,728
+18,834
+68% +$139K ﹤0.01% 809
2025
Q3 		$216K Buy
27,894
+10,156
+57% +$76.7K ﹤0.01% 764
2025
Q2 		$123K Buy
+17,738
New +$141K ﹤0.01% 874

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Quadrature Capital's BCYC Position: Q2 2026 in Review

Quadrature Capital opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 104,092 shares worth $441K. The stake represents ﹤0.01% of the portfolio and ranks #1056 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in BCYC as recently as Q4 2025.

Quadrature Capital first reported a position in BCYC in Q2 2025 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Quadrature Capital held 104,092 shares of Bicycle Therapeutics worth $441K as of Q2 2026.
  • Bicycle Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Bicycle Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1056 holding.
  • Quadrature Capital first reported a position in Bicycle Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.